Codexis (CDXS) Restructuring Costs (2022 - 2023)

Codexis' (CDXS) quarterly Restructuring Costs came in at $3.1 million in Q3 2023, up 4261.11% quarter-over-quarter from $72000.0 in Q2 2023.

Codexis (CDXS) Restructuring Costs (2022 - 2023) Analysis & Trends

Codexis' Restructuring Costs history runs 2 years deep, the most recent figure standing at $3.1 million for Q3 2023.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $3.1 million in Q3 2023; TTM through Jun 2024 was $3.1 million, a 5.16% decrease from a year earlier, with the FY2025 full-year figure at $3.4 million, changed N/A from the prior year.
Restructuring Costs advanced to $3.1 million in Q3 2023 per CDXS's latest filing, from $72000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $3.2 million in Q4 2022 and bottomed at $72000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Codexis	180.63 Mn	115.49 Mn	13.18 Mn

Download Data